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432a Tuesday, February 18, 2014arrhythmogenic early afterdepolarizations (EADs) characteristic of LQT2 my-
ocytes under b-adrenergic stimulation. Parameters of Ca handling were
measured in ventricular myocytes isolated from normal and LQT2 hearts using
confocal Ca imaging and whole-cell patch clamp. Ca imaging revealed no
LQT2-mediated changes in amplitude of Ca transients and SR Ca content under
basal conditions. Experiments in saponin-permeabilized cells using SR-
entrapped low-affinity Ca indicator revealed enhanced RyR-mediated SR Ca
leak and SERCA-mediated Ca uptake in LQT2 myocytes. Correspondingly,
western blot analyses using phospho-specific antibodies showed that phosphor-
ylation of both RyR and phospholamban is significantly higher in LQT2 CMs
vs. controls at both PKA and CaMKII sites. In the presence of isoproterenol (50
nM) LQT2 CMs exhibited diminished Ca transient amplitudes and SR Ca con-
tent compared to controls. Stimulation of LQT2 CMs with isoproterenol re-
sulted in prolongation of plateau of action potentials accompanied by
aberrant Ca releases and phase 3 EADs, in contrast to controls. Importantly,
preincubation of LQT2 CMs with CaMKII inhibitor KN93 (10 min, 500 nM)
prevented ISO-mediated changes in AP duration, disturbances in Ca handling
and EADs. Analysis of CaMKII activity revealed no differences between
LQT2 and control heart tissues, while Western-blot analysis demonstrated
~30% decrease in the abundance of catalytic subunit of protein phosphatase
type 1 (PP1). These data suggest that hyperactive RyRs due to adaptive reduc-
tion in PP1 activity and thereby RyR hyperphosphorylation is a key contributor
to enhanced triggered activity in hereditary LQT2 syndrome.
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Intracellular calcium plays a role in a host of cellular functions ranging from
synaptic transmission to gene expression. As a transient, short-range signaling
molecule, calcium is often presented in complex signal patterns, including os-
cillations and bursts. The concerted action of pumps, channels, and buffers in
conjunction with the ion-impermeable cell membrane tightly regulates these
calcium signals spatially and temporally but simultaneously impedes our ability
to study the action of calcium. Many techniques measure changes in intracel-
lular calcium, providing insights into the specificity of these signal patterns,
but fewer are capable of controlling calcium levels in cells. Patch clamp pipette
access can be used to modulate calcium in small numbers of cells, but larger
scale control often requires disruption of normal calcium signaling using drugs
such as thapsigargin, in order to couple intracellular calcium to an external cal-
cium signal. Here we present a new technology to rapidly modulate intracel-
lular calcium. Using supported nanotubes called ‘‘nanostraws,’’ we
demonstrate direct ionic delivery into cells. The dimensions of the nanostraws
(~100 nm x 1 mm tall) allow them to spontaneously penetrate the cell, thereby
allowing calcium to bypass the lipid membrane and its constituent calcium
channels through the nanostraws. Calcium delivery is controlled by fluid
flow, and intracellular calcium oscillations can be induced and modulated in
amplitude and frequency. While previous studies have perturbed long-term
cell behavior using nanostraws and similar systems, here we apply the tech-
nique to transient signaling by rapid intracellular calcium modulation and char-
acterize the spatiotemporal delivery using calcium indicators (e.g. Fluo-4,
GCaMP6). By circumventing the intrinsic calcium regulatory mechanisms,
nanostraws provide direct access and the ability to mimic biological calcium
oscillations, adding a new method for decoding the role of calcium signal pat-
terns and their effects on downstream signaling.Platform: Ion Channels and Disease
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Cystic fibrosis (CF) is a chronic lethal genetic disease, which is caused by mu-
tations in the cystic fibrosis transmembrane conductance regulator (CFTR)gene. F508del - deletion of a single phenylalanine residue at position 508 - is
the most common lethal mutation found in CF patients. Fully synthesized
F508del-CFTR is rapidly degraded in the endoplasmic reticulum due to
F508del-induced misfolding, preventing proper transport of the protein to the
epithelial cell membrane. In previous work, we have demonstrated that
F508del facilitates partial unfolding and consequent aggregation of the first
nucleotide-binding domain in human CFTR (hNBD1). This F508del-
faciliated aggregation is likely a key contributor in F508del-CF pathogenesis.
These findings established a foundation to develop a new high-throughput bio-
physical screen to identify compounds that directly bind to the hNBD1 domain
to prevent the F508del-hNBD1 aggregation in vitro and thereby stabilize
F508del-CFTR in vivo. We used computational protein engineering to construct
an equivalently stable hNBD1 variant that reacts with a visible fluorophore
exclusively at a single labeling site. Fluorescence self-quenching of this labeled
domain upon unfolding/aggregation provides a robust assay for stabilizing com-
pounds, and this assay gives a Z-factor 0.8 in high-throughput screening. We
will describe thermodynamic and structural studies on compounds identified us-
ing this screen as well as progress in implementing an equivalent screen in
models of full-length human CFTR. Our results demonstrate that thermody-
namic stabilization of a protein via interaction of a small molecule at a site
remote from a mutation can indirectly correct a genetic defect.
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G551D, the third most common pathogenic mutation in CF, exhibits an
extremely low Po because ATP fails to increase its activity. Although
VX-770 (Ivacaftor) improves the symptoms of patients carrying the G551D
mutation, it is insufficient to completely rectify this gating abnormality. In
excised inside-out patches, we found that VX-770 increases the ATP-
independent Po of WT-CFTR by ~ 9-fold, a magnitude very similar to the
effect of VX-770 on G551D-CFTR (12.8 5 1.9 fold, n = 12), suggesting a
common mechanism of action: VX-770 simply shifts the equilibrium of
ATP-independent gating towards the open state. However, upon ATP removal
VX-770-potentiated macroscopic G551D-CFTR currents increases initially by
~2-fold (1.655 0.48, n = 3), followed by a slow decay. Such a biphasic time
course suggests two ATP binding sites with opposite effects and different affin-
ities. We hypothesize that the G551D mutation converts the low-affinity ATP-
binding site (i.e., site 2) to an inhibitory site, whereas the high-affinity site 1
remains stimulatory. This hypothesis predicts that lowering [ATP] could actu-
ally increase the G551D-CFTR current. Indeed, replacing 2 mM ATP with 20
mMATP increases the current by ~ 2-fold. To further test this idea, we mutated
W401 and Y1219, two aromatic amino acids known to interact with ATP in site
1 and site 2 respectively. While ATP removal increases G551D/W401G cur-
rents by ~ 2-fold (2.12 5 0.12, n = 8), a mono-phasic current decrease is
seen with G551D/Y1219G-CFTR. However, the relaxation time constants for
the current decay phase for G551D and G551D/Y1219 (41.8 5 1.0 s and
32.4 5 1.6 s respectively) are significantly longer than that of G551D/
W410G (28.85 0.5 s). These results point to a unique mechanism underlying
CF pathogenesis by the G551D mutation.
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Influenza A develops amantadine resistance within days in tissue culture or
infection. The amantadine-resistant mutant, M2 S31N, has become globally
dominant in human isolates. Infection of MDCK cells by a pandemic 2009
H1N1 strain, bearingM2 S31N, was blocked by low-micromolar concentrations
for a set of amantadine analogs previously shown to block several M2-WT influ-
enza strains from H1N1, H2N2, and H3N2 subtypes. Three sets of variants were
synthesized to explore SAR properties. One demonstrated that opening the
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than 2 carbons. Pre-exposing the virus to drug before inoculation showed inac-
tivation and exposure-recovery of the virus on the ~10-minute time scale. Resis-
tance development is dramatically reduced. For selected compounds, 10
passages (~5 weeks) in the presence of drug were required before the 2009
H1N1 developed resistance. However, themechanism of action is unclear. Lipo-
some assays indicate direct block of S31N M2 (22-62). But 2009 H1N1
M2-transfected HEK cells are not blocked, either on the 2- or the 30-minute
time scales. Yet, the revertant (N31S) is well blocked. Solid state NMR suggests
that drugs bind to the S31N transmembrane peptide domain. The resistant strains
developed in the presence of these drugs show no mutations in M2, but a few
mutations in hemagglutinin. It is possible that these hydrophobic amines func-
tion partly by neutralizing the endosome. However, the virus pre-exposure
results indicate a direct effect on the virus, not just on the endosome. The
A/WSN/33 virus is not blocked by these drugs in cytopathic effect assays, but
the revertant (N31S) is, indicating for A/WSN/33 that the M2-block is the key
effect. In summary, resistance-invulnerable drugs for the 2009 H1N1 influenza
A virus have been identified and the mechanism of action is yet to be defined.
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Cellular targets of Liþ, such as glycogen synthase kinase 3b and G proteins, have
been long implicated in bipolar disorder (BPD) etiology. However, recent genetic
studies linkBPD to other proteins, in particular ion channels. Liþ affects neuronal
excitability, but the underlying mechanisms and the relevance to putative BPD
targets are unknown. We discovered a novel, dual regulation of G protein-
gated Kþ channels (GIRK) by Liþ, and determined the underlying molecular
mechanisms. In hippocampal neurons, therapeutic doses of Liþ, 0.5-2 mM,
increased GIRK basal current (Ibasal) but attenuated neurotransmitter-evoked
GIRK currents (Ievoked) mediated by Gi/o-coupled G protein-coupled receptors
(GPCRs). Molecular mechanisms of these regulations were studied with heterol-
ogously expressed GIRK1/2. In excised membrane patches, Liþ increased Ibasal
but reduced GPCR-induced GIRK currents. Both regulations were membrane-
delimited and G protein-dependent, requiring both Ga and Gbg subunits. Liþ
did not impair direct activation of GIRK by Gbg, suggesting that inhibition of
Ievoked results from a Li
þ action on Ga, probably through inhibition of GTP-
GDP exchange. In direct binding studies, Liþ promoted GPCR-independent
dissociation of Gai
GDP from Gbg by a Mg2þ-independent mechanism. This pre-
viously unknown Liþ action on G proteins explains the second effect of Liþ, the
enhancement of GIRK’s Ibasal. The dual effect of Li
þ on GIRK may profoundly
regulate inhibitory effects of neurotransmitters acting via GIRKs. Our findings
link between Liþ, neuronal excitability, and both cellular and genetic targets of
BPD: GPCRs, G proteins and ion channels.
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Activatedmicroglia significantly contribute to the secondary inflammatory dam-
age in ischemic stroke and therefore constitute attractive targets for post-infarct
intervention. Microglia express the voltage-gated Kv1.3 and the calcium-
activated KCa3.1 channels, both of which have been reported to be involved
in microglia mediated neuronal killing, oxidative burst and inflammatory cyto-
kine production. However, most of these experiments have been performedwith
cultured neonatalmicroglia and it has always been questionedwhether these cul-
tures accurately reflect the Kþ channel expression of activatedmicroglia in adult
brain. Following intrahippocampal LPS injection or middle cerebral artery
occlusion (MCAO) with 7 days of reperfusion we observed Kv1.3 and KCa3.1
immunoreactivity on activated microglia in mouse brain. In both conditions
we further detected currents exhibiting the biophysical and pharmacological
properties of Kv1.3 and KCa3.1 on microglia immediately following isolated
with CD11b-magnetic beads. Channel expression was significantly higher
than on microglia isolated from control brains. We next investigated the effect
of genetic deletion and pharmacological blockade of KCa3.1 on the reperfusion
injury following ischemic stroke using reversible MCAO as a model. KCa3.1-/-
mice and wild-type mice treated with the KCa3.1 blocker TRAM-34 exhibited
significantly smaller infarct areas and improved neuronal survival and motorcoordination in neurological deficit test on day-7 after MCAO. Kv1.3 blockade
with PAP-1 exhibited similar beneficial effects in wild-type mice but did not
further reduce infarct area or improve neurological deficit in KCa3.1-/- mice.
In male Wistar rats combined blockade of both Kv1.3 and KCa3.1 with PAP-1
and TRAM-34 also did not further reduce infarct area compared to treatment
with either TRAM-34or PAP-1 alone suggesting that blockade of onemicroglial
Kþ channel is sufficient to improve outcomes in ischemic stroke.
Supported by RO1 GM076063 from the National Institute of Health.
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A large scale sequencing endeavor (Epi4K Consortium, Nature 501:217-221,
2013) recently reported discovery of several de novomutations in genes encod-
ing ion channels, neurotransmitter receptors and other proteins that may explain
severe, early onset childhood epilepsy. One intriguing variant was found in
KCNB1, encoding KV2.1. Although KV2.1 is a potassium channel involved
in repolarization of neuronal action potentials, it has not previously been asso-
ciated with epilepsy. The reported variant (T374I) was heterozygous and af-
fects a highly conserved residue within the KV2.1 ion selectivity filter 5
amino acids N-terminal to the GYG motif. We performed heterologous expres-
sion of wildtype (WT) and mutant KV2.1 channels and used whole-cell patch
clamp recording to define the functional consequences of the mutation and to
infer the pathophysiology of the epilepsy. Wild-type or mutant KV2.1 channels
were transiently expressed under control of the CMV promoter in CHO cells.
Expression of channel subunits was confirmed by co-expression of a fluores-
cent protein encoded by the same plasmid. Cells expressing homomeric
WT-KV2.1 exhibited large outward currents with rapid voltage-dependent acti-
vation and slow inactivation. By contrast, cells expressing homomeric KV2.1-
T374I exhibited no outward or inward current. Our findings suggest that this
mutation impairs ion permeation and confers a loss-of-function as the molecu-
lar basis for epilepsy. Further studies will evaluate the impact of mutant sub-
units on formation of functional heteromultimeric channels to explore
possible dominant-negative behavior.
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The human voltage-gated proton channel (hHv1) is a transmembrane protein
responsible for selective proton permeation across cell membranes in nasal mu-
cosa, sperm, and white blood cells. Its pathological states include male infer-
tility, allergies, and diseases such as cystic fibrosis, asthma, and lupus. Its
involvement in ischemic stroke and invasiveness of breast cancer cells has sub-
stantiated hHv1 as a therapeutic target for drug designs for which require the
understanding of hHv1 structure and proton conduction mechanism. We
recently constructed and validated a homology model (Kulleperuma et al.,
2013) of hHv1 characterized by the presence of a salt bridge between anionic
D112 and cationic R208 side chains in the narrow region of the hydrated pore.
Thanks to the pairing of these and other charged residues in ionic networks, the
distribution of charged and polar residues in the wild-type channel is a priori
compatible with permeation of either cations or anions. However, a static-
field electrostatic barrier opposing cation movement arises in neutral mutants
of residue D112, consistent with the observation that these mutants are selec-
tive to anions (Musset et al., 2011). Our recent experiments show that proton
selectivity is restored in double mutant D112V/V116D, while D112S and
D112V/D116S are anion-selective and D112V does not conduct ions. Atom-
istic molecular dynamics simulations of these mutants in lipid bilayers show
that their structures differ in the organization of ionic side chains in the external
vestibule and suggest that, consistent with the above analysis, the distribution
